iShares Global Infrastructure ETF (IGF)

Creative Planning trimmed its holdings in shares of iShares Global Infrastructure ETF (NASDAQ: IGF) by 39.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,335 shares of the company's stock after selling 31,627 shares during the period. Creative Planning's holdings in

Barings LLC acquired a new stake in iShares Global Infrastructure ETF (NASDAQ: IGF) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 32,327 shares of the company's stock, valued at approximately $1,914,000. A number of other hedge funds also recently added

The article compares SPDR S&P Global Infrastructure ETF (GII) and iShares Global Infrastructure ETF (IGF), both tracking the S&P Global Infrastructure Index. Downgrade to 'hold' due to high prices, stagnating momentum, and increased volatility; a better entry point may come after a price correction. IGF is favored over GII for its superior liquidity and lower expense ratio, despite GII's slightly better risk-adjusted metrics and lower volatility.

I hunt investments that combine safety, income, and growth, avoiding hype and focusing on long-term, high-quality opportunities. Some areas are unloved and undervalued, offering income, potential growth, and protection against inflation, perfect for patient investors. I seek places with professional management, liquidity, and dual potential, giving me both steady income and the chance for capital gains.

Thanks to AI, cloud computing, and renewable energy reshaping the global economy, one under-the-radar sector surging to the forefront is utilities. Long considered a sleepier, more defensive, “old economy” play, utilities stocks and ETFs are quickly becoming the backbone of the digital and green revolution.

IGF should benefit from increasing investment in infrastructure, particularly in emerging economies. The ETF is well-positioned and has exposure to several positive longer-term trends. Top holdings include firms such as airport operators, toll road operators, and utilities. This mix provides stable cash flows and attractive dividend prospects.

Looking for an investment theme that is working this year despite tariff headwinds and recession concerns? Global infrastructure ETFs are at the top of the winners list, with positive returns YTD.

Infrastructure is a crucial foundation for any kind of society attempting to expand beyond a handful of individual, nearby homesteads in order to form a community.

SAN FRANCISCO and SUZHOU, China , March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved SYCUME® (teprotumumab N01, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody) for the treatment of thyroid eye disease (TED). As China's first and the world's second approved IGF-1R antibody drug, SYCUME® has ended a 70-year drought of no new treatment option for TED in China.

Thematic ETFs have had a tough slog – now headed for a third-straight year of losses. Roughly 90 thematic ETFs debuted back in 2021, compared to fewer than 20 this year.

Infrastructure investment, is crucial for economic growth and stability, essential for cities' functioning and growth. iShares Global Infrastructure ETF invests in large-cap companies across the energy, utilities, and transportation sectors. Global population growth, urban expansion, and sustainability challenges highlight the increasing demand for innovative infrastructure solutions.

SAN FRANCISCO and SUZHOU, China , May 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, today announced that the New Drug Application (NDA) for IBI311, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, has been accepted and granted priority review designation by the Center for Drug Evaluation (CDE) of the China National Drug Administration (NMPA) for the treatment of Thyroid Eye Disease (TED). IBI311 is the first anti-IGF-1R antibody with NDA submitted in China.

The industrial sector, particularly industries relating to heavy machinery, is thriving. Industrials balance growth and income.

GRID: Excellent Smart Grid ETF For The Global Electrification Theme

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease (TED) and low clinical activity score (CAS), which is a measure of disease activity. The trial includes patients with an initial diagnosis of TED between two to 10 years prior to the study and low levels of disease activity. Findings from this study will build on a separate Phase 3 clinical trial (OPTIC-J) that is currently underway in Japan and is evaluating TEPEZZA for the treatment of TED patients with disease duration of nine months or less and higher levels of disease activity. TED is a serious, progressive and potentially vision-threatening rare autoimmune disease that can cause proptosis (eye bulging), diplopia (double vision), eye pain, redness and swelling.1 TEPEZZA was approved by the U.S. Food and Drug Administration (FDA) in January 2020 and is the first and only medicine for TED, regardless of TED activity or duration. TEPEZZA has not been approved for commercial use in Japan. There are no medicines approved for the treatment of TED in Japan. This randomized, double-masked, placebo-controlled, parallel-group, multicenter trial will be evaluating the efficacy, safety and tolerability of TEPEZZA compared to placebo in adults with chronic TED and low CAS. All study participants will be required to have a CAS of ≤2 at the screening and baseline visits, two to 10 years since initial diagnosis of TED, and no worsening in proptosis, diplopia or inflammatory symptoms of TED for at least one year. Adult participants who meet the trial eligibility criteria will be randomized in a 2:1 ratio to receive an infusion of either TEPEZZA or placebo, 10 mg/kg for the first infusion and 20 mg/kg for the remaining seven infusions, once every three weeks, for a total of eight infusions. The primary efficacy endpoint is proptosis response rate at Week 24, defined as the percentage of participants with at least a 2 mm reduction in proptosis from baseline in the study eye, without deterioration in the fellow eye (≥ 2 mm increase). Study participants who complete the treatment period and are proptosis non-responders at Week 24 may choose to enter an open-label extension period to receive an additional eight infusions of TEPEZZA. “We know that patients who have lived with Thyroid Eye Disease for quite some time may continue to experience debilitating symptoms that impact their day to day lives and activities,” said Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, Horizon. “Therefore, it’s important that we explore the efficacy of TEPEZZA in those with more chronic disease. We are grateful to have the opportunity to work with local researchers, regulators and patients on this trial to accomplish that goal.” The trial was designed in consultation with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). More information about the trial, including eligibility criteria, is available on the Japan Registry of Clinical Trials website (trial ID number jRCT2031220730). About Thyroid Eye Disease (TED) TED is a serious, progressive and potentially vision-threatening rare autoimmune disease.1 It often occurs in people living with Graves’ disease, but is a distinct disease that is caused by autoantibodies activating an insulin-like growth factor-1 receptor (IGF-1R)-mediated signaling complex on cells within the retro-orbital space.2,3 This leads to a cascade of negative effects, which may cause long-term, irreversible damage, including blindness.4,5 Early signs and symptoms of TED may include dry eyes and grittiness; redness, swelling and excessive tearing; eyelid retraction; proptosis; pressure and/or pain behind the eyes; and diplopia. About TEPEZZA Teprotumumab is marketed as TEPEZZA (teprotumumab-trbw) in the United States. Teprotumumab is not currently approved for commercial use in Japan. INDICATION TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate. Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA. Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA. ADVERSE REACTIONS The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders. Please see Full Prescribing Information or visit TEPEZZAhcp.com for more information. About Horizon Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements regarding the potential benefits of TEPEZZA as a treatment of TED; the expected scope and design of clinical trials and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to clinical trials, including potential delays in completing clinical trials and the fact that prior results may not predict future clinical trial outcomes; risks related to regulatory approvals; impacts of the COVID-19 pandemic and actions taken to slow its spread; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information. References